Keywords: Inflammatory bowel disease; Ulcerative colitis; Biological therapy; Biosimilar; Infliximab; Adalimumab; CT-P13; Switching;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: adalimumab; etanercept; indirect comparison; psoriasis;
Keywords: abatacept; ACPA; adalimumab; cost effectiveness; economic model; ICER; QALY; rheumatoid arthritis; treatment costs;
Keywords: AZA; azathioprine; ADA; adalimumab; CYA; cyclosporine A; CYX; cyclophosphamide; ETN; etanercept; FK; tacrolimus; IFX; infliximab; IS; immunosuppressant; LFM; leflunomide; MMF; mycophenolate mofetil; MTX; methotrexate; RTX; rituximab; TAK; Takayasu's Arter
Keywords: Adalimumab; Anti-TNF; Crohn's disease; Fistulae; Infliximab; Stenosis;
Keywords: adalimumab; etanercept; non-TNF-α biologics; real-world effectiveness; rheumatoid arthritis; TNF-α inhibitors;
Keywords: Adalimumab; Etanercept; Omalizumab; Insulin; Injection site reactions; Systemic hypersensitivity reactions; MoAbs; TNF-α inhibitors;
Keywords: Juvenile idiopathic arthritis; Uveitis; Adalimumab; Tocilizumab; Biologics;
Keywords: TNF Inhibitor; IBD Treatment; Patient Management; Inflammation; ADA; adalimumab; CD; Crohn's disease; IBD; inflammatory bowel disease; IFX; infliximab; IM; immunomodulator; IQR; interquartile range; TNF; tumor necrosis factor; UC; ulcerative colitis;
Keywords: MTX; methotrexate; TNF; tumor necrosis factor; IL; interleukin; CTLA4; cytotoxic T-lymphocyte antigen 4; IFX; infliximab; ADA; adalimumab; GLM; golimumab; CZP; certolizumab pegol; ETN; etanercept; TCZ; tocilizumab; ABA; abatacept; RTX; rituximab; UTK; ust
Keywords: ADA; adalimumab; AEs; adverse events; AZA; azathioprine; CI; confidence interval; Cy; cyclosporine; CNS; central nervous system; CS; corticosteroids; CYC; cyclophosphamide; CZP; certolizumab pegol; ePOST; Extrapulmonary Physician Organ Severity Tool; ETN;
Keywords: Adalimumab; Crohn's disease; Inflammatory bowel disease; Long term therapy; Steroid dependency;
Keywords: Anticorps; biothérapies; calprotectine fécale; maladie de Crohn; maladies inflammatoires; chroniques intestinales; rectocolite hémorragique; Antibodies; biotherapy; fecal calprotectin; Crohn's disease; intestinal inflammatory disease; ulcerative coliti
Keywords: Adalimumab; Infliximab; Etarnecept; Ustekinumab; Psoriasis; Drugs therapies; Polymorphisms; Effectiveness;
Keywords: ABA; abatacept; ADA; adalimumab; AIx; augmentation index; AMI; acute myocardial infarction; ANA; anakinra; Apo; apolipoprotein; AS; ankylosing spondylitis; CTZ; certolizumab pegol; CV; cardiovascular; CVD; cardiovascular disease; DMARD; disease-modifying
Keywords: adalimumab; alcoholism; dermatoethics; distributive justice; ethics; methotrexate; psoriasis; tumor necrosis factor-α inhibitor;
Keywords: adalimumab; biologics switch; etanercept; PASI (Psoriasis Area and Severity Index); psoriasis; ustekinumb
Keywords: acne inversa; adalimumab; anakinra; biologics; etanercept; hidradenitis suppurativa; infliximab; treatment; tumor necrosis factor–alfa; ustekinumab
Keywords: Adalimumab; Golimumab; Infliximab; Ulcerative colitis
Keywords: Biologic therapy; Dose reduction; Adalimumab; Etanercept; Infliximab; UstekinumabTerapia biológica; Reducción de dosis; Adalimumab; Etanercept; Infliximab; Ustekinumab
Keywords: Hidradenitis suppurativa; Acne inversa; Surgery; Biologic therapy; Systemic treatment; AdalimumabHidradenitis supurativa; Acné inversa; Cirugía; Terapia biológica; Terapia sistémica; Adalimumab
Keywords: Terapia biológica; Reducción de dosis; Adalimumab; Etanercept; Infliximab; UstekinumabBiologic therapy; Dose reduction; Adalimumab; Etanercept; Infliximab; Ustekinumab
Keywords: adalimumab; biologics; etanercept; infliximab; monitoring; psoriasis; psoriatic arthritis; safety; screening; ustekinumab; AAD; American Academy of Dermatology; ALP; alkaline phosphatase; ALT; alanine transaminase; ANA; antinuclear antibody; AST; aspartat
Keywords: Biologics; Dermatology; Etanercept; Adalimumab; Infliximab; Ustekinumab; Secukinumab; IVIG;
Keywords: Thiopurines; Infliximab; Adalimumab; Surgery; Hospitalization; Infection; CD; Crohn's disease; CI; confidence interval; HR; hazard ratio; TNF; tumor necrosis factor;
Keywords: Psoriasis; Clinical equivalence; Meta-analysis; Biologic agents; Infliximab; Ustekinumab; Adalimumab; EtanerceptPsoriasis; Equivalencia clínica; Metaanálisis; Biológicos; Infliximab; Ustekinumab; Adalimumab; Etanercept
Keywords: Adalimumab; Anti-tumour necrosis factor alpha antibodies; Crohn's disease; Post-surgical recurrence
Keywords: Crohn's disease; Infliximab; Adalimumab; Perianal fistula; AgeDoença de Crohn; Infliximabe; Adalimumabe; Fístula perianal; Idade
Keywords: Rheumatoid arthritis; TNF-α inhibitors; Retention rate; Etanercept; Adalimumab; Infliximab;
Keywords: AZA; azathioprine; CDAI; Crohn's disease activity index; 95% CI; 95% confidence interval; CRP; C-reactive protein; CD; Crohn's disease; HGPRT; hypoxanthine-guanine phosphoribosyl transferase; HPLC; high performance liquid chromatography; IBD; inflammatory
Keywords: Ulcerative colitis; Infliximab; Adalimumab; Certolizumab pegol; Appropriateness; Treatment discontinuation;
Keywords: adalimumab; adherence; claims data; etanercept; golimumab; pharmacoeconomic;
Keywords: Adalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Intensificación; Cambio (switching); Fracaso secundarioAdalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Escalation; Switching; Maintenance failure
Keywords: Adalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Escalation; Switching; Maintenance failureAdalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Intensificación; Cambio (switching); Fracaso secundario
Keywords: ADA; adalimumab; CD; Crohn disease; CDAI; Crohn's Disease Activity Index; CrI; credible interval; CZP; certolizumab pegol; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IL-12/23; interleukin 12/23; NAT; natalizumab; OR; odds ratio;
Keywords: A; absenteeism; ADA; adalimumab; CD; Crohn's disease; CPC; conventional proctocolectomy and Brooke ileostomy; CZP; certolizumab pegol; HPWAW; hours per week actually worked; HPWFP; productivity and hours per week fully productive; IBD; inflammatory bowel
Keywords: Anti-tumor necrosis factor; Infliximab; Adalimumab; Golimumab; Certolizumab pegol; Complications; Infusion reactions; Autoimmune disease;
Keywords: Adalimumab; Crohn's disease; Cryptococcosis; Manure; Chickens;
Keywords: Ulcerative colitis; Anti-TNF; Adalimumab; Surgery; Colectomy;
Keywords: Cherubism; Tumor necrosis factor α; Adalimumab; SH3-binding protein 2;
Keywords: Infliximab; Adalimumab; Response; Growth; Inflammatory markers;
Keywords: Drug reimbursement; Systematic review; Evidence development; Imatinib; Pegfilgrastim; Adalimumab;
Keywords: Adalimumab; Immunogenicity; Anti-drug antibodies; Human monoclonal antibodies; Anti-idiotype Antibodies
Keywords: Efficacy; Effectiveness; Inflammatory bowel disease; Infliximab; AdalimumabEficacia; Efectividad; Enfermedad inflamatoria intestinal; Infliximab; Adalimumab
Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAgâ) on anti-TNF therapy have a low rate of reactivation
Keywords: IMID; immune-mediated inflammatory diseases; anti-HBc; antibody to hepatitis B core antigen; HBsAg; hepatitis B surface antigen; IBD; inflammatory bowel disease; TB; tuberculosis; HBV; hepatitis B virus; RA; rheumatoid arthritis; AGA; American Gastroenter
TNF-alpha inhibition could reduce biomarkers of endothelial dysfunction in patients with moderate to severe psoriasis: A 52-week echo-Doppler based quasi-experimental study
Keywords: Microvessels; Nails/blood supply; Psoriasis; Ultrasonography; Doppler; Vascular resistance; Adalimumab; Microvascularización; Uñas/aporte sanguÃneo; Psoriasis; EcografÃa; Doppler; Resistencia vascular; Adalimumab;
Tubérculo coroideo asintomático en un paciente con enfermedad de Crohn en tratamiento con adalimumab
Keywords: Adalimumab; Terapia biológica; Tuberculosis miliar; Tubérculo coroideo; Enfermedad de Crohn; Adalimumab; Biological therapy; Miliary tuberculosis; Choroidal tubercle; Crohn's disease;
Introduction of a glycosylation site in the constant region decreases the aggregation of adalimumab Fab
Keywords: Adalimumab; Aggregation; Antibody; Fab; Glycosylation;
A novel engineered interchain disulfide bond in the constant region enhances the thermostability of adalimumab Fab
Keywords: Adalimumab; Antibody; Disulfide bond; Fab; Thermal stability;
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease
Keywords: Adalimumab; Crohn disease; Infliximab; Ulcerative Colitis;